Strata Critical Medical (SRTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, with voting open until May 27, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 14, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of Class II Directors for terms expiring in 2029, with nominees William A. Heyburn and Andrew Lauck.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.
Advisory vote on the compensation of named executive officers (say-on-pay).
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Latest events from Strata Critical Medical
- Q2 2026 revenue up 60.7% year-over-year, with strong growth and margin expansion forecast.SRTA
Investor presentation - Q2 2026 revenue up 60.7% to $72.5M; Adjusted EBITDA and 2026 guidance both increased.SRTA
Q2 2026 - Integrated transplant logistics leader leverages tech, regulatory shifts, and M&A for rapid growth.SRTA
16th Annual East Coast IDEAS Conference - Director elections, auditor ratification, and executive pay all approved amid board transitions.SRTA
AGM 2026 - Strong Q1 2026 growth and industry leadership position support continued expansion and profitability.SRTA
Investor presentation - Revenue up 87% to $67.4M, net income positive, and guidance reaffirmed for 2026.SRTA
Q1 2026 - Asset-light, agnostic transplant logistics platform drives rapid growth and national expansion.SRTA
25th Annual Needham Virtual Healthcare Conference - Proxy covers director elections, auditor ratification, and executive pay amid a strategic business shift.SRTA
Proxy filing - Q2 2024 delivered 11.4% revenue growth, positive Adjusted EBITDA, and record Medical results.SRTA
Q2 2024